136 related articles for article (PubMed ID: 28101733)
1. 3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.
Sarrut D; Badel JN; Halty A; Garin G; Perol D; Cassier P; Blay JY; Kryza D; Giraudet AL
EJNMMI Phys; 2017 Dec; 4(1):6. PubMed ID: 28101733
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.
Giraudet AL; Cassier PA; Iwao-Fukukawa C; Garin G; Badel JN; Kryza D; Chabaud S; Gilles-Afchain L; Clapisson G; Desuzinges C; Sarrut D; Halty A; Italiano A; Mori M; Tsunoda T; Katagiri T; Nakamura Y; Alberti L; Cropet C; Baconnier S; Berge-Montamat S; Pérol D; Blay JY
BMC Cancer; 2018 Jun; 18(1):646. PubMed ID: 29884132
[TBL] [Abstract][Full Text] [Related]
3. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (
Wahl RL; Frey EC; Jacene HA; Kahl BS; Piantadosi S; Bianco JA; Hammes RJ; Jung M; Kasecamp W; He B; Sgouros G; Flinn IW; Swinnen LJ
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204102
[TBL] [Abstract][Full Text] [Related]
4. α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10.
Li HK; Sugyo A; Tsuji AB; Morokoshi Y; Minegishi K; Nagatsu K; Kanda H; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T; Hasegawa S
Cancer Sci; 2018 Jul; 109(7):2302-2309. PubMed ID: 29952132
[TBL] [Abstract][Full Text] [Related]
5. FZD10-targeted α-radioimmunotherapy with
Sudo H; Tsuji AB; Sugyo A; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T
Cancer Sci; 2022 Feb; 113(2):721-732. PubMed ID: 34935247
[TBL] [Abstract][Full Text] [Related]
6. 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT.
Gosewisch A; Ilhan H; Tattenberg S; Mairani A; Parodi K; Brosch J; Kaiser L; Gildehaus FJ; Todica A; Ziegler S; Bartenstein P; Böning G
EJNMMI Res; 2019 Aug; 9(1):76. PubMed ID: 31414241
[TBL] [Abstract][Full Text] [Related]
7. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy.
Vergnaud L; Giraudet AL; Moreau A; Salvadori J; Imperiale A; Baudier T; Badel JN; Sarrut D
EJNMMI Phys; 2022 May; 9(1):37. PubMed ID: 35575946
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
9. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
10. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
11. Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies.
Matesan M; Fisher DR; Wong R; Gopal AK; Green DJ; Sandmaier BM; Bensinger W; Pagel JM; Orozco J; Press OW; Cassaday RD; Hutchinson E; Wanner M; Pal S; Thostenson C; Rajendran JG
J Nucl Med; 2020 Sep; 61(9):1300-1306. PubMed ID: 32169919
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of three chelates reveals DOTAGA promising for
Sudo H; Tsuji AB; Sugyo A; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T
Cancer Sci; 2023 Dec; 114(12):4677-4690. PubMed ID: 37781962
[TBL] [Abstract][Full Text] [Related]
15. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
[TBL] [Abstract][Full Text] [Related]
18. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
19. Simplified image-based dosimetry using planar images and patient-specific S-values.
Kim KM; Suh M; Cheon GJ; Lee MS; Lee JS
Med Phys; 2024 Feb; ():. PubMed ID: 38340367
[TBL] [Abstract][Full Text] [Related]
20. Pre-dosing with lilotomab prior to therapy with
Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
